2022年12月15日

頂級投資財團包括新投資者ARCH Venture Partners、Gates Frontier、Bezos Expeditions、Reliance Digital Health Limited、Greenoaks、Alumni Ventures、Moore Strategic Ventures和Project X，現有投資者包括Khosla Ventures、NeuroTechnology investors、METIS、Forepont Capital Partners、ID8 Investments、盛大集團和墨爾本大學。資金將加速產品開發，促進關鍵臨床試驗的啟動，並推動Synchron在癱瘓治療方麵獲得同類BCI市場的首個批準。下載加載媒體播放器…Stentrode™在血管內手術中通過頸靜脈植入大腦運動皮層。Stentrode™在血管內手術中通過頸靜脈植入大腦運動皮層。美國東部標準時間2022年12月15日上午08:00紐約——(美國商業資訊)——血管內腦機接口(BCI)公司Synchron今天宣布獲得由ARCH Venture Partners領投的7500萬美元C輪超額認購。蓋茨前沿、貝佐斯探險、信實數字健康有限公司、Greenoaks、Alumni Ventures、Moore Strategic Ventures和Project X作為新的額外投資者加入ARCH。現有投資者包括Khosla Ventures、NeuroTechnology investors、METIS、Forepont Capital Partners、ID8 Investments、盛大集團和墨爾本大學參與了本輪融資。C輪融資使該公司自成立以來的總融資額達到1.45億美元。這筆資金將加速Synchron的首個平台產品(Synchron Switch™BCI)的開發，並啟動關鍵的臨床試驗。 Ari Nowacek from ARCH Venture Partners will join Synchron’s Board of Directors, and ARCH Co-Founder and Managing Director Robert Nelsen will join as Board Observer. “We have an opportunity to deliver a first-in-class commercial BCI. The problem of paralysis is much larger than people realize. 100 million people worldwide have upper limb impairment,” said Tom Oxley, M.D., Ph.D., CEO & Founder, Synchron. “We are extremely excited to work with ARCH and this world-class syndicate to bring this technology to the people who need it.” “At ARCH, our approach has always been to pair great science and technology with remarkable teams to build disruptive companies. The technology we witnessed at Synchron is helping people with previously untreatable conditions regain connection to the world. It is an exciting time for neurotechnology,” said ARCH Co-Founder and Managing Director Robert Nelsen. The Synchron Switch™ brain computer interface is implanted in the blood vessel on the surface of the motor cortex of the brain via the jugular vein, through a minimally-invasive endovascular procedure. Once implanted, it is designed to detect and wirelessly transmit motor intent out of the brain, restoring a capability for severely paralyzed patients to control personal devices with hands-free point-and-click. Synchron has an ongoing US clinical trial, COMMAND, that assesses the impact on daily tasks such as texting, emailing, online shopping, and telehealth services. The FDA granted Breakthrough Device designation to Synchron in August 2020 and an Investigational Device Exemption in July 2021. The first US patient was implanted in July 2022 at Mount Sinai in New York. View Synchron CEO 2022 TED Talk , “A brain implant that turns your thoughts into text.” About Synchron Synchron is a clinical-stage endovascular brain computer interface (BCI) company. Since 2012, the company has been developing a BCI platform that avoids the need for open brain surgery by using a minimally-invasive procedure. The Synchron Switch™ BCI received FDA Breakthrough Device Designation in 2020, and is currently in human clinical trials in the US and Australia. Synchron has been published in multiple peer-reviewed journals including Nature Biotechnology, Nature Biomedical Engineering and JNIS. Synchron is based in Brooklyn, New York with R&D facilities in Melbourne, Australia. For more information, visit www.synchron.com . Follow us on Twitter @synchroninc . Contacts